The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Launched by PHILIP KERN · Sep 10, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how two medications, mirabegron and tadalafil, affect blood sugar levels in people who are at risk of developing diabetes, specifically those who are prediabetic and obese. The researchers believe that mirabegron can help improve how the body handles glucose, or sugar, and that combining it with tadalafil may enhance these benefits. Participants will be given one of these medications, a combination of both, or a placebo (a harmless pill with no active ingredients) for 14 weeks. The goal is to see if these treatments can help reverse prediabetes.

To be eligible for this trial, participants should be between 18 and 75 years old, have a specific range of blood sugar levels (Hemoglobin A1C between 5.7 and 6.4), and have a body mass index (BMI) between 27 and 45. However, individuals with diabetes, certain medical conditions, or those taking specific medications will not be able to participate. If you join the trial, you’ll be helping researchers understand how these medications work for people at risk of diabetes, and you may benefit from improved health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hemoglobin A1C between 5.7 and 6.4
• • Body mass index between 27 and 45
• Exclusion Criteria:
• • Diabetes
• • Chronic use of any antidiabetic medications
• • Any unstable medical condition
• • Use of steroids or daily use of NSAIDS
• • History of chronic inflammatory conditions
• • Use of anticoagulants
• • Contraindications to the use of mirabegron or tadalafil
• • Any condition deemed risky by the study physician